A Drug Compendium based analysis of Selective Serotonin Reuptake Inhibitors (SSRIs)Drugs available in Indian market

Background: Depression is a prevalent mental health disorder requiring lifelong pharmacological treatment. Selective Serotonin Reuptake Inhibitors (SSRIs) are widely prescribed due to their favourable safety and efficacy profiles. In India, the presence of multiple brands with varied pricing calls for an evaluation to guide rational prescribing.

Aim: To evaluate different brands of Selective Serotonin Reuptake Inhibitors (SSRIs) available in the Indian market.

Objectives: To assess the spectrum of brands, explore available formulations and strengths, determine the cost variation among different SSRIs, and identify key factors influencing pricing differences.

Materials and Methods: An observational study was conducted at GCS Medical College and Hospital. Data were sourced from the latest edition of the Indian Drug Review (IDR), Issue 3, 2024. Analysis included brand names, formulations, strength variations, and maximum and minimum costs, excluding incomplete entries.

Results: Wide cost variations were observed among SSRIs. The maximum variation was seen with Paroxetine 20 mg (229%), followed by Sertraline 50 mg (211.42%), and Escitalopram 5 mg (174.28%). Fluoxetine showed the highest formulation variety (tablets, capsules, suspension, syrup), while Paroxetine demonstrated the broadest range of strengths (10 mg to 40 mg). Among Fixed Dose Combinations (FDCs), Fluoxetine 20 mg + Olanzapine 5 mg had the highest cost variation (69.14%), and Escitalopram combined with Clonazepam was the most common FDC observed.

Conclusion: Significant cost disparities among SSRIs underline the need for cost-conscious prescribing practices to enhance treatment adherence and reduce economic burden on patients